Rossari Biotech Limited

Rossari Biotech Limited

Rossari Biotech Limited has announced an earnings conference call for investors and analysts to discuss its Q2 & H1 FY27 financial results, scheduled for October 19, 2026.

Rossari Biotech Limited

Rossari Biotech Limited has submitted a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialisation of shares, mutilation and cancellation of share certificates, and substitution of depository names in the register of members for the quarter ended September 30, 2026.

Rossari Biotech Limited

Rossari Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed for all designated persons and their immediate relatives from October 1, 2026, till 48 hours after the announcement of unaudited financial results for the quarter and half year ending on September 30, 2026.

Rossari Biotech Limited

Rossari Biotech Limited has announced an investor meet/conference/event on September 22, 2026, where they will discuss financial and other information available to the public. The meeting may be subject to change due to exigencies.

Rossari Biotech Limited

Rossari Biotech Limited has announced an investors and analysts meet/conference/events on September 10, 2026, in Mumbai. The meeting will discuss the company's financial and other information available to the public or covered in the 'Earnings Presentation' submitted to the Stock Exchange on July 19, 2026. The date and time of the meeting are subject to change due to exigencies.

Rossari Biotech Limited

Rossari Biotech Limited has informed that it will not be participating in the Nirmal Bang's Semi-Annual Investor Conference scheduled for August 10, 2026.

Rossari Biotech Limited

Rossari Biotech Limited has announced an investor meet/conference on August 10, 2026, at 2:00 PM IST in Mumbai. The discussion will be based on the financial and other information available to the public or covered in the 'Earnings Presentation' submitted to the Stock Exchange on July 19, 2026.

Rossari Biotech Limited

Rossari Biotech Limited has released the transcript of its Q1 FY27 earnings conference call, held on July 20, 2026. The company reported its highest ever quarterly revenue and EBITDA, with consolidated revenue growing 28% YoY. The performance was driven by healthy momentum in the domestic business and the expansion of its international presence. The company emphasized its focus on innovation, diversified portfolio, and disciplined execution. It also highlighted its strengths in the agrochemical sector and its capabilities across agro-surfactants, emulsifiers, and adjuvants.

Rossari Biotech Limited

Rossari Biotech Limited held its 17th Annual General Meeting on July 20, 2026, through video conferencing. The meeting was attended by all directors and other participants. The company received 3 letters from corporate members appointing their representatives, aggregating to 14.87% of the total paid-up equity share capital. The meeting passed all resolutions with the requisite majority.

Rossari Biotech Limited

Rossari Biotech Limited has made available the audio recording of its Q1 FY 27 earnings conference call on its website.

Rossari Biotech Limited

Rossari Biotech Limited has corrected an error in their previous announcement regarding the grant of options under the Rossari Employee Stock Option Plan 2019, stating that 5000 options were granted instead of 4000.

Rossari Biotech Limited

Rossari Biotech Limited announced its Q1 FY27 results, with a 28% YoY increase in revenue to Rs. 697.2 crore, and a 19% YoY increase in EBITDA to Rs. 80.6 crore. PAT increased by 4% to Rs. 35.1 crore.

Rossari Biotech Limited

Rossari Biotech Limited has informed the Exchange about Investor Presentation for Q1 FY27 Earnings Presentation.

Rossari Biotech Limited

Rossari Biotech Limited has published a copy of newspaper publication of extract of Consolidated Unaudited Financial Results for the Quarter ended June 30, 2026, as per Regulation 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Rossari Biotech Limited

Rossari Biotech Limited has announced the outcome of its Board meeting, which approved unaudited financial results for the quarter ended June 30, 2026, grant of options under the Rossari Employee Stock Option Plan - 2019, allotment of equity shares under the same plan, and transfer of 100% shareholding of Rossari International Limited Company to Rossari (Singapore) Pte. Ltd.

Rossari Biotech Limited

Rossari Biotech Limited has announced the grant of 4000 options under Rossari Employee Stock Option Plan - 2019, allotment of 2500 equity shares, and transfer of 100% shareholding of Rossari International Limited Company to Rossari (Singapore) Pte. Ltd.

Rossari Biotech Limited

Rossari Biotech Limited has announced the allotment of 2500 equity shares under the Rossari Employee Stock Option Plan - 2019, and the transfer of 100% shareholding of Rossari International Limited Company to Rossari (Singapore) Pte. Ltd. as part of an internal group restructuring exercise.

Rossari Biotech Limited

Rossari Biotech Limited has announced the outcome of its board meeting, which approved unaudited financial results for the quarter ended June 30, 2026, grant of options under the Rossari Employee Stock Option Plan - 2019, allotment of equity shares under the same plan, and transfer of 100% shareholding of Rossari International Limited to Rossari (Singapore) Pte. Ltd.

Rossari Biotech Limited

Rossari Biotech Limited will host a conference call on July 20, 2026, to discuss its Q1 FY27 results, which will be declared on July 18, 2026.

Rossari Biotech Limited

Rossari Biotech Limited has received a compliance certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of shares, mutilation, and cancellation of share certificates for the quarter ended June 30, 2026.